Biocon has posted its June 2025 quarter results, and the numbers tell an interesting story.

The company’s sales grew 15% YoY, rising from ₹3,433 crore in June 2024 to ₹3,942 crore this year. Operating performance also improved, with EBIDT (earnings before interest, depreciation, and tax) up 21% YoY, from ₹620 crore to ₹749 crore. This shows the core business is generating more revenue and operational profits. However, the big concern lies in profitability. Net profit has plunged 95% YoY, dropping from ₹862 crore to just ₹89.2 crore. This sharp fall has directly hit EPS (earnings per share), which crashed 96%, from ₹5.49 to just ₹0.23. This indicates that despite higher sales and operating profits, other factors—possibly higher interest costs, depreciation, exceptional losses, or one-off expenses—have heavily eroded the bottom line. On valuation, the stock trades at ₹364 with a market cap of ₹48,692 crore and a high PE ratio of 120.2, meaning investors are paying a steep price compared to current earnings. In short: Biocon’s revenue and operations are growing, but profits have collapsed. For investors, this means the company needs to fix its cost structure or address the reasons behind the profit wipeout before the high valuation can be justified. This is a classic case of “top line up, bottom line down,” and it’s a reminder that sales growth alone doesn’t guarantee shareholder returns.